Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma-Reference-Cited by-同舟云学术

Co‐targeting bromodomain and extra‐terminal proteins and MCL1 induces synergistic cell death in melanoma

Published:2020-04-24 Issue:8 Volume:147 Page:2176-2189
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Tseng Hsin‐Yi¹²³^ORCID,Dreyer Jan¹,Emran Abdullah Al¹²³,Gunatilake Dilini¹²,Pirozyan Mehdi¹²³,Cullinane Carleen⁴⁵,Dutton‐Regester Ken²⁶,Rizos Helen²⁷,Hayward Nicholas K.²⁶,McArthur Grant⁸,Hersey Peter¹²³^ORCID,Tiffen Jessamy¹²³,Gallagher Stuart¹²³^ORCID

Affiliation:

1. Melanoma Immunology and Oncology The Centenary Institute Camperdown New South Wales Australia

2. Melanoma Institute Australia Wollstonecraft New South Wales Australia

3. Central Clinical School The University of Sydney Camperdown New South Wales Australia

4. Translational Research Laboratory Peter MacCallum Cancer Centre Melbourne Victoria Australia

5. Oncogenic Signalling and Growth Control Program Peter MacCallum Cancer Centre Melbourne Victoria Australia

6. Oncogenomics Laboratory QIMR Berghofer Medical Research Institute Brisbane Queensland Australia

7. Faculty of Medicine and Health Sciences Macquarie University Sydney New South Wales Australia

8. Department of Cancer Medicine Peter MacCallum Cancer Centre Melbourne Victoria Australia

Funder

Cancer Council NSW

National Health and Medical Research Council

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33000

Reference51 articles.

1. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

2. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

3. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

4. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

5. Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti‐CTLA‐4 treatment;Pigment Cell & Melanoma Research;2024-05-09

2. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors;International Journal of Molecular Sciences;2024-03-19

3. Roles and mechanisms of aberrant alternative splicing in melanoma — implications for targeted therapy and immunotherapy resistance;Cancer Cell International;2024-03-10

4. IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics;Journal of Investigative Dermatology;2023-07

5. Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins;International Journal of Molecular Sciences;2023-03-04